Aadi Bioscience, Inc. (NASDAQ:AADI) Q4 2022 Earnings Call Transcript

Scott Giacobello: Sure. Neil, do you want to take that one?

Neil Desai: Yes, sure. At this time we haven’t really spoken about the timing of data from that, but as Scott mentioned and Loretta mentioned, the timing of the initiation of the trial is in Q2 at this point and that’s the information we have from Mirati. It is a Phase 1 trial where, because it’s a combination the dose needs to be worked out and so I think we can understand that that takes the usual amount of time for figuring out a combination. So I don’t think we expect any results this year, but it’s possible we might get something next year. But again, that we have to hear from Mirati.

Unidentified Analyst: Thank you. Thank you for taking my questions.

Operator: That concludes today’s question-and-answer session. I’d like to turn the call back to Scott Giacobello for closing remarks.

Scott Giacobello: Yes, I want to thank everyone for joining us today. As you can see, we’re very excited about 2023 and looking forward to sharing more information later in the year. Thank you all.

Operator: This concludes today’s conference call. Thank you for participating. You may now disconnect.